NO20083248L - Imidazoler som GABA-B reseptormodulatorer - Google Patents

Imidazoler som GABA-B reseptormodulatorer

Info

Publication number
NO20083248L
NO20083248L NO20083248A NO20083248A NO20083248L NO 20083248 L NO20083248 L NO 20083248L NO 20083248 A NO20083248 A NO 20083248A NO 20083248 A NO20083248 A NO 20083248A NO 20083248 L NO20083248 L NO 20083248L
Authority
NO
Norway
Prior art keywords
compounds
alkyl
treatment
gaba
imidazoles
Prior art date
Application number
NO20083248A
Other languages
English (en)
Inventor
Udo Bauer
Linda Gustafsson
Maria Saxin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083248L publication Critical patent/NO20083248L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser som har en positiv allosterisk GABAB reseptor (GBR) modulerende effekt, fremgangsmåter for fremstilling av nevnte forbindelser og deres anvendelse, eventuelt i kombinasjon med en GABAB agonist, for inhibering av forbigående lavere spiserørlukkemuskelrelaksasjoner, for behandling av gastrospiserørreflukssykdom, så vel som for behandling av funksjonelle gastrointestinale forstyrrelser og irritabel tarmsyndrom (IBS). Forbindelsene er representert ved den generelle formelen (I) hvori R1, R2, R3 og R4 er som definert i beskrivelsen. For eksempel kan enhver alkyl eller arylalky, R2 være alkyl, R3 kan være alkoksy og R4 kan være en substituent som inneholder en arylgruppe.
NO20083248A 2005-12-23 2008-07-22 Imidazoler som GABA-B reseptormodulatorer NO20083248L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502905 2005-12-23
PCT/SE2006/001463 WO2007073299A1 (en) 2005-12-23 2006-12-21 Imidazoles as gaba-b receptor modulators

Publications (1)

Publication Number Publication Date
NO20083248L true NO20083248L (no) 2008-07-23

Family

ID=38188930

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083248A NO20083248L (no) 2005-12-23 2008-07-22 Imidazoler som GABA-B reseptormodulatorer

Country Status (12)

Country Link
US (1) US20080312305A1 (no)
EP (1) EP1968946A4 (no)
JP (1) JP2009521429A (no)
KR (1) KR20080090448A (no)
CN (1) CN101341131A (no)
AU (1) AU2006327316A1 (no)
BR (1) BRPI0620373A2 (no)
CA (1) CA2632020A1 (no)
IL (1) IL191767A0 (no)
NO (1) NO20083248L (no)
WO (1) WO2007073299A1 (no)
ZA (1) ZA200805160B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
CN101384558A (zh) * 2005-12-23 2009-03-11 阿斯利康(瑞典)有限公司 Gaba-b受体调节剂
KR20080091452A (ko) * 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
CN107445919A (zh) 2010-03-12 2017-12-08 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US10653672B2 (en) * 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
BR112017022936A2 (pt) 2015-04-24 2018-07-17 Omeros Corp inibidores da pde10 e composições e métodos relacionados
SG11201710694YA (en) 2015-06-22 2018-01-30 Sumitomo Dainippon Pharma Co Ltd Bicyclic heterocyclic amide derivative
JP6692354B2 (ja) 2015-06-22 2020-05-13 大日本住友製薬株式会社 １，４−ジ置換イミダゾール誘導体
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
JP6896701B2 (ja) 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876655A (en) * 1971-08-18 1975-04-08 Beecham Group Ltd Anti-inflammatory acyl imidazoles
US4659720A (en) * 1982-12-20 1987-04-21 Merck & Co., Inc. 5-amino or substituted amino imidazoles useful to treat coccidiosis
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
DE4213750A1 (de) * 1992-04-25 1993-10-28 Basf Ag Verfahren zur Herstellung von 3-(Hydroxyphenyl)-propionaldehyden und gegebenenfalls der Herstellung von 3-(hydroxyphenyl)-propanolen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
AU5859598A (en) * 1996-12-24 1998-07-17 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
CN100341862C (zh) * 2001-09-14 2007-10-10 三菱制药株式会社 噻唑烷衍生物及其医药用途
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
KR20080091452A (ko) * 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
CN101384558A (zh) * 2005-12-23 2009-03-11 阿斯利康(瑞典)有限公司 Gaba-b受体调节剂
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
AU2008241604A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric GABAB receptor modulator effect
US20080262064A1 (en) * 2007-04-18 2008-10-23 Astrazeneca Ab Novel Compounds For The Treatment Of GI Disorders 682

Also Published As

Publication number Publication date
IL191767A0 (en) 2008-12-29
BRPI0620373A2 (pt) 2011-11-08
JP2009521429A (ja) 2009-06-04
EP1968946A4 (en) 2010-05-05
AU2006327316A1 (en) 2007-06-28
CN101341131A (zh) 2009-01-07
CA2632020A1 (en) 2007-06-28
ZA200805160B (en) 2009-10-28
WO2007073299A1 (en) 2007-06-28
EP1968946A1 (en) 2008-09-17
US20080312305A1 (en) 2008-12-18
KR20080090448A (ko) 2008-10-08

Similar Documents

Publication Publication Date Title
NO20083248L (no) Imidazoler som GABA-B reseptormodulatorer
NO20083247L (no) GABA-B reseptormodulatorer
NO20083244L (no) Heterosykliske GABA-B modulatorer
NO20083249L (no) Imidazolderivater for behandling av gastrointestinale forstyrrelser
NO20083243L (no) Pyrazoler for behandling av GERD og IBS
EA200870489A1 (ru) Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1
SMT201300085B (it) Composti di pirrolo
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
EA200800341A1 (ru) Арил- и гетероарилзамещенные тетрагидробензазепины и их применение для блокировки обратного захвата норэпинефрина, допамина и серотонина
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
PE20091425A1 (es) Derivados de aminotiazol
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
EA200901098A1 (ru) Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов
NO20084262L (no) Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EA200702468A1 (ru) Новые производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
NO20091678L (no) Modulatorer av glucokortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og deres anvendelse
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application